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Aim of the present study was to assess the hepatoprotective activity of goat milk on
antitubercular drug-induced hepatotoxicity in rats. Hepatotoxicity was induced in rats
using a combination of isoniazid, rifampicin, and pyrazinamide given orally as a suspen-
sion for 30 days. Treatment groups received goat milk along with antitubercular drugs.
Liver damage was assessed using biochemical and histological parameters. Administration
of goat milk (20 mL/kg) along with antitubercular drugs (Group III) reversed the levels of
serum alanine aminotransferase (82 ± 25.1 vs. 128.8 ± 8.9 units/L) and aspartate amino-
transferase (174.7 ± 31.5 vs. 296.4 ± 56.4 units/L, p< 0.01) compared with antitubercular
drug treatment Group II. There was a significant decrease in serum alanine aminotrans-
ferase (41.8 ± 4.1 vs. 128.8 ± 8.9 units/L, p< 0.01) and aspartate aminotransferase
(128.8 ± 8.54 vs. 296.4 ± 56.4 units/L, p< 0.001) levels in Group IV (goat milk 40 mL/kg)
compared with antitubercular drug treatment Group II. Goat milk (20 mL/kg and 40 mL/kg)
was effective in reversing the rise in malondialdehyde level compared with the antitu-
bercular drug suspension groups (58.5 ± 2 vs. 89.88 ± 2.42 mmol/mL of tissue homogenate,
p< 0.001 and 69.7 ± 0.78 vs. 89.88 ± 2.42 mmol/mL of tissue homogenate, p< 0.001, respec-
tively). Similarly, both doses of milk significantly prevented a fall in superoxide dismutase
level (6.23 ± 0.29 vs. 3.1 ± 0.288 units/mL, p < 0.001 and 7.8 ± 0.392 vs. 3.1 ± 0.288 units/mL,
p< 0.001) compared with the group receiving antitubercular drugs alone. Histological ex-
amination indicated that goat milk reduced inflammation and necrotic changes in hepa-
tocytes in the treatment groups. The results indicated that goat milk prevented the
antitubercular drug-induced hepatotoxicity and is an effective hepatoprotective agent.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).acology, School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar- Delhi
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Antitubercular drug-induced hepatotoxicity is one of the
most challenging clinical problems. It is the main cause of
interruption during a tuberculosis treatment course and
may lead to hospitalization or life threatening events [1,2].
Antitubercular drug-induced hepatotoxicity has a wide
spectrum of presentations, ranging from an asymptomatic
mild rise in liver biochemical tests to acute hepatitis and
acute liver failure. It is reported to be mediated through
oxidative stress, which leads to lipid peroxidation and an
alteration in antioxidant levels in the body [3]. Lipid perox-
idation results in cell damage due to oxidative degradation
of lipids present in cell membranes. In response to delete-
rious effects of free radical-induced lipid peroxidation, cells
activate antioxidant defense mechanisms in which super-
oxide dismutase and reduced glutathione act synergistically
to detoxify the effects of lipid peroxidation [3]. Therefore, it
is suggested that the agents which reduce the lipid peroxide
content in tissue and increase the intracellular antioxidant
defenses may have protective effects on the liver in people
taking antitubercular treatment. Currently very few reliable
liver-protective drugs are available in the allopathic arma-
mentarium. Their effects are unsatisfactory and they add to
the pill burden. Management of drug-induced hepatotoxicity
is still a challenge to modern medicine. Therefore, there is a
strict need to screen herbal products and nutraceuticals
which can be taken by the patients as food during the
treatment of tuberculosis.
Goat milk is a food of high nutritional value as it is rich in
various physiologically functional components, including
proteins, vitamins (such as vitamins E and C), flavonoids, and
carotenoids with antioxidant properties [4e7]. Goat milk is
considered to possess high antioxidant activity that resists
oxidative stability and highly protects consumers from expo-
sure to oxidative stress [8]. It has been reported that goat milk
consumption potentiates liver divalent metal transporter 1
expression thereby enhancing Fe metabolism and storage
indicating its potential in anemia [9]. Furthermore, few studies
have also demonstrated its anti-inflammatory and antioxi-
dant properties which indicate that goat milk may possess
hepatoprotective activity [10e13]. Goatmilk is easily available,
easy to digest, and can be taken as food during drug treatment
of tuberculosis. The hepatoprotective activity of goat milk in
antitubercular drug-induced hepatotoxicity has not yet been
investigated. The rationale of the present studywas to explore
the effect of goat milk on antitubercular drug-induced hepa-
totoxicity in rats.2. Materials and methods
Healthy adult albino rats of either sex of Wistar strain
weighing 200e300 g were used after approval of the Institu-
tional Ethics Committee. They were housed in standard lab-
oratory conditions at 25 ± 2C with a 12 hour light/dark cycle.
Animals were given free access to a rat chow diet andwater ad
libitum. Before conducting experiments, animals were accli-
matized to laboratory conditions for 7 days.2.1. Induction of hepatotoxicity
Experimental antitubercular drug-induced hepatotoxicity was
produced by administration of isoniazid, rifampicin, and
pyrazinamide (HþRþZ) suspension daily orally for 30 days.
The doses of antitubercular drugs (H: 27 mg/kg, R: 54mg/kg, Z:
135 mg/kg/d; Kwality Pharmaceuticals Pvt. Ltd., Amritsar,
Punjab, India) were extrapolated from daily human doses
using a conversion table [14]. Gum acacia was used as a sus-
pending agent. In the vehicle control group, 2% gum acacia
(10 mL/kg) was administered to the rats. For induction of
hepatotoxicity, a combination of calculated doses of H, R, and
Z suspended in 2% gum acacia were administered to rats
orally.
The animals were divided into five groups (n¼ 6). The
groups were treated as follows:
Group I: vehicle control, i.e., 2% gum acacia orally for 30
days.
Group II: (HþRþZ) suspension orally for 30 days.
Group III: (HþRþZ) suspensionþ goat milk 20 mL/kg orally
for 30 days.
Group IV: (HþRþZ) suspensionþ goat milk 40 mL/kg orally
for 30 days.
Group V: (HþRþZ) þ silymarin (standard) 50 mg/kg orally
for 30 days.
Blood samples of animals from all the groups were taken
on 30th day by cardiac puncture under ether anesthesia. After
sacrificing the animals, livers were removed for histopatho-
logical examination and biochemical parameters were
investigated.
2.2. Assessment of liver damage
2.2.1. Gross morphological assessment
Liverswere excised from the rats andwere rinsedwith normal
saline. They were weighed after blotting with filter paper. The
liver indices were calculated as a percentage of the body
weight [15]. A gross morphological assessment was then
performed for hepatic lesions based on the qualitative pro-
cedure developed by Mitchell et al [16]. They were graded as
follows: 0, no lesions; 1þ, minimal damage; 2þ, mild to mod-
erate damage; and 3þ, severe damage.
Each liver was excised into two pieces. The right lobe was
immersed in isotonic 10% buffered formalin fixative for his-
tological assessment while the left lobe was rinsed using cold
physiological saline and then homogenized with cool phos-
phate buffer saline for malondialdehyde and superoxide dis-
mutase (SOD) assays.
2.2.2. Histopathological examination
All the groups were subjected to histological examination.
Microscopic examination was done by a qualified pathologist
using hematoxylin and eosin staining in a blinded fashion.
2.2.3. Biochemical estimations
Serum alanine aminotransferase (ALT) and serum aspartate
aminotransferase (AST) were estimated using the Reitman
and Frankel method [17]. Tissue malondialdehyde and SOD
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method, and Ohkawa et al [19] method.
2.3. Statistical analysis
The values were expressed as mean ± standard error of the
mean. One-way analysis of variance, followed by an appro-
priate post hoc test (Tukey's test) were used for analysis.3. Results
The mean body and liver weights noted in all groups are
shown in Table 1. One rat fromGroup I and Group II died at the
beginning of the experiment for unknown reasons. There was
a statistically significant reduction in the percentage change
of the mean body weight in the HþRþZ suspension group
compared with the vehicle control group (11.26 vs. 7.97,
p< 0.05). Treatment with goat milk and silymarin (Table 1)
caused a marked increase in the body weight compared with
the HþRþZ suspension group (12.5 vs. 11.26, p< 0.05; 10.37
vs. 11.26, p< 0.05; and 6.45 vs. 11.26, p< 0.05, respectively).
3.1. Gross morphological assessment
The morphological index in Group II was significantly high
compared with Group I (2.83 vs. 0, p< 0.001). Group III revealed
a significant reduction in morphological score compared with
Group II (0.83 vs. 2.83, p< 0.001). Group IV showed a significant
decrease in morphological score compared with Group II (0.5
vs. 2.83, p< 0.001). Group V also showed a decrease in
morphological score but it was still higher than Group III and
Group IV (Table 2).
3.2. Histological examination
The histological examination of the liver tissue showed
normal hepatic architecture in Group I (Figure 1). Adminis-
tration of antitubercular drugs for 30 days to Group II pro-
duced hepatocellular damage indicated by necrosis with
hepatocyte infiltration. Coadministration of goat milk (20 mL/
kg) with antitubercular drugs reduced histological changes
like inflammation and necrosis. In Group IV, after coadmin-







1 Group I 326 ± 3.33 352 ± 9.69
2 Group II 293 ± 14.7 260 ± 17.7
3 Group III 200 ± 3.33 225 ± 8.46
4 Group IV 241 ± 8.33 266 ± 8.71
5 Group V 310 ± 8.47 330 ± 7.71
Liver index was calculated as (liver weight/bodyweight 100%). The value
analyzed using one-way analysis of variance followed by Tukey honest s
* p< 0.05.
a When compared with vehicle control group.
b When compared with the antituberculosis drug group.
c When compared with the silymarin group.very scanty inflammation was observed. It maintained the
normal histology of liver tissue and showed almost a reversal
from the degenerative and necrotic changes caused by anti-
tubercular drugs. The effects of goat milk were comparable to
silymarin.
3.3. Biochemical estimations
3.3.1. Serum ALT and AST
In the present study, Group II, which received antitubercular
drugs for 30 days, showed a rise in serum ALT (128.8 ± 8.9 vs.
50.75 ± 3.40 units/L, p< 0.01) and AST (296.4 ± 56.4 vs.
181.75± 7.88 units/L, p< 0.05) comparedwith the control group.
Administration of goat milk (20 mL/kg) along with antituber-
cular drugs reversed the levels of serum ALT (82 ± 25.1 vs.
128.8± 8.9 units/L) andAST (174.7± 31.5 vs. 296.4± 56.4 units/L,
p< 0.01) compared with the antitubercular drug treatment
group. There was also significant decrease in serum ALT
(41.8 ± 4.1 vs. 128.8 ± 8.9 units/L, p< 0.01) and AST levels
(128.8 ± 8.54 vs. 296.4 ± 56.4 units/L, p< 0.001) in Group IV (goat
milk 40 mL/kg) compared with the antitubercular drug treat-
ment group, i.e., Group II. Moreover, the effects were compa-
rable to Group V, i.e., the silymarin treated group (Table 2).
3.3.2. Malondialdehyde and SOD activity
The lipid peroxidation activity of liver homogenate in Group II
(89.88 ± 2.42 mmol/mL of tissue homogenate) was significantly
raised compared with Group I (60.1 ± 3.24 mmol/mL of tissue
homogenate; p< 0.001). Lipid peroxidation reduced signifi-
cantly in both the goat milk treated groups compared with the
antitubercular drug treatment group (58.5 ± 2 vs. 89.88 ± 2.42
mmol/mL of tissue homogenate, p< 0.001 and 69.7 ± 0.78 vs.
89.88 ± 2.42 mmol/mL of tissue homogenate, p< 0.001; Table 2).
The reduction was higher in Group III (58.5 ± 2.0 mmol/mL of
tissue homogenate) than in Group IV (69.7 ± 0.78 mmol/mL of
tissue homogenate) and was similar to Group V (54.55 ± 1.96
mmol/mL of tissue homogenate). Table 2 shows the effect of
different pharmacological interventions on SOD activity in
liver homogenate. SOD activity showed a significant decrease
in Group II compared with the vehicle control group (3.1 ± 0.28
vs. 8.15 ± 0.99 units/mL, p< 0.001). Coadministration of goat
milkwith the antitubercular drugs significantly increased SOD
activity in Group III and Group IV (6.23 ± 0.29 and 7.8 ± 0.39
units/mL) compared with antitubercular drug treatmentt groups.
Percent change (%) Liver
weight (g)
Liver index (%)
7.97 9.76 ± 0.51 2.77
11.26a,* 11.65 ± 0.52 4.48a,*
12.5b,c,* 10.95 ± 0.32 4.86a,*
10.37b,c,* 9.95 ± 0.35 3.74
6.45b,* 9.84 ± 0.69 2.98b,*
s were expressed asmean ± standard error of themean. The data was
ignificant difference test.
Table 2 e Comparison of different parameters measured in experimental groups of rats.
Biochemical parameters Group I Group II Group III Group IV Group V
ALT (units/L) 50.75 ± 3.4 128.8 ± 8.9a,** 82 ± 25.1 41.8 ± 4.1b,** 38 ± 1.9c,***
AST (units/L) 181.75 ± 7.88 296.4 ± 56.4a,* 174.7 ± 31.5b,** 128.8 ± 8.54c,*** 121.2 ± 8.61c,***
MDA (mmol/mL of tissue homogenate) 60.1 ± 3.24 89.88 ± 2.42a,*** 58.5 ± 2b,c,**,*** 69.7 ± 0.78c,*** 54.55 ± 1.96c,***
SOD (units/mL) 8.15 ± 0.99 3.1 ± 0.28a,*** 6.23 ± 0.29c,*** 7.8 ± 0.39c,*** 6.62 ± 0.55c,***
MI (0e3) 0 (0e0) 2.83 (2e3)a,*** 0.83 (0e2)c,*** 0.5 (0e2)c,*** 0.16 (0e1)c,***
The values were expressed asmean ± standard error of themean. The data was analyzed using one-way analysis of variance followed by Tukey
honest significant difference test.
* p < 0.05.
** p< 0.01.
*** p < 0.001.
ALT¼ alanine aminotransferase; AST¼ aspartate aminotransferase; MDA¼malondialdehyde; MI¼morphological index; SOD¼ superoxide
dismutase.
a When compared with the vehicle control group.
b When compared with the antituberculosis drug group.
c When compared with the silymarin group.
Figure 1 e Photomicrograph of the liver tissue. (A) Vehicle control group: showing the normal histology of liver tissue; (b)
Isoniazid, rifampicin, and pyrazinamide (HþRþZ) group: showing necrosis with hepatocyte infiltration; c) HþRþZ þ goat
milk (20 mL/kg): showing normal hepatocytes and decreased necrosis: (D) HþRþZ þ goat milk (40 mL/kg): showing almost
recovery to normal histology; (e) HþRþZ þ silymarin (50 mg/kg): showing normal hepatocytes (hematoxylin and eosin
stain, £50).
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statistically significant difference in both groups. Similarly,
the effects observed in Group III and Group IV were compa-
rable to Group V (6.23 ± 0.29 vs. 6.62 ± 0.55 units/mL and
7.8 ± 0.39 vs. 6.62 ± 0.55 units/mL).4. Discussion
Antitubercular drug-induced hepatotoxicity is mediated
through oxidative stress and free radical damage to hepato-
cytes. Due to the leakage of enzymes from damaged hepa-
tocytes into vascular compartments, serum AST and ALT
levels increase in hepatic damage. Treatment with antitu-
bercular drugs increases malondialdehyde concentration
which leads to lipid peroxidation. Lipid peroxidation is an
important mechanism of hepatotoxicity and plays a key role
in the pathogenesis of several human diseases. SOD is an
antioxidant enzyme which catalyzes the dismutation of the
superoxide (O2
) radical into either ordinary molecular oxygen
or hydrogen peroxide. The decrease in SOD activity could be
due to the increased production of reactive oxygen species as
evident from the increased lipid peroxidation levels due to
antitubercular drug treatment [20,21]. Liver biopsy is the
most reliable index of liver damage. Parameters like degen-
eration, necrosis, and fibrosis indicate liver damage while a
reduction in these parameters suggests hepatoprotection.
Administration of antitubercular drugs also results in
inflammation, degeneration, and necrotic changes in rat
liver.
In the present study, concurrent administration of goat
milk (20 mL/kg and 40 mL/kg) along with antitubercular drugs
was found to be effective in reducing the severity of hepato-
toxicity, and the effects were similar to the reference drug
silymarin. Administration of goat milk reduced inflammation
and necrotic changes. It significantly prevented a rise in levels
of serum ALT, AST, and tissue malondialdehyde. Similarly,
goat milk significantly prevented a fall in SOD compared with
the group receiving antitubercular drugs alone. The beneficial
results of goat milk in both groups were equivalent to the
reference drug silymarin. However, the difference between
the two groups receiving goat milk was not statistically sig-
nificant. Although the higher dose (40 mL/kg) was safe and
tolerable, no additional beneficial effects were observed.
These findings suggest that goat milk possesses the potential
of an effective and promising option for the treatment of
hepatotoxicity.5. Conclusion
The present study showed that goat milk prevents antitu-
bercular drug-induced hepatotoxicity. Therefore, it may be
concluded that goat milk possesses hepatoprotective activity
and can be considered as an effective hepatoprotective agent.Conflicts of interest
The authors have no financial or proprietary interest in any of
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